Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5705250 | Ophthalmology | 2017 | 8 Pages |
Abstract
The choice of primary treatment for group D retinoblastoma should be carefully weighed, because according to this study, 13% of eyes harbor high-risk histopathologic features at presentation, with the absence of vitreous seeds being a potential risk factor. It is of special importance in group D eyes being considered for nonsystemic treatment, such as primary intraophthalmic artery chemotherapy. Secondary enucleated group D eyes with high-risk histopathologic features more commonly involved anterior structures, warranting meticulous clinical and histologic examinations for this subset of patients.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Ido D. MD, Andrew W. MD, Tanzina MRCPCH, PhD, Catriona MBBS, MRCPCH, Esin K. MD, Irene MD, M. Ashwin MD, FRCOphth, Mandeep S. PhD, FRCS(Ed),